XTX Topco Ltd Takes $666,000 Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

XTX Topco Ltd acquired a new position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 14,801 shares of the company's stock, valued at approximately $666,000.

Other institutional investors have also recently added to or reduced their stakes in the company. GAMMA Investing LLC grew its stake in shares of Protagonist Therapeutics by 749.2% in the third quarter. GAMMA Investing LLC now owns 552 shares of the company's stock worth $25,000 after purchasing an additional 487 shares in the last quarter. Exchange Traded Concepts LLC bought a new position in shares of Protagonist Therapeutics in the third quarter worth $43,000. CWM LLC grew its stake in shares of Protagonist Therapeutics by 910.3% in the third quarter. CWM LLC now owns 1,273 shares of the company's stock worth $57,000 after purchasing an additional 1,147 shares in the last quarter. Harvest Fund Management Co. Ltd bought a new position in shares of Protagonist Therapeutics in the third quarter worth $69,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Protagonist Therapeutics by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,130 shares of the company's stock worth $95,000 after purchasing an additional 379 shares in the last quarter. 98.63% of the stock is currently owned by institutional investors.

Protagonist Therapeutics Stock Up 1.7 %

Shares of NASDAQ PTGX traded up $0.70 during mid-day trading on Friday, hitting $41.08. 530,557 shares of the company traded hands, compared to its average volume of 743,232. Protagonist Therapeutics, Inc. has a 1 year low of $20.10 and a 1 year high of $48.89. The stock has a market capitalization of $2.45 billion, a price-to-earnings ratio of 15.53 and a beta of 2.18. The business has a 50 day moving average of $44.46 and a two-hundred day moving average of $40.40.

Insider Activity

In related news, insider Arturo Md Molina sold 1,906 shares of the stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $40.98, for a total value of $78,107.88. Following the completion of the sale, the insider now directly owns 46,444 shares of the company's stock, valued at approximately $1,903,275.12. This represents a 3.94 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Suneel Gupta sold 103,437 shares of the stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $46.04, for a total value of $4,762,239.48. Following the completion of the sale, the insider now directly owns 256,174 shares of the company's stock, valued at approximately $11,794,250.96. This represents a 28.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 209,863 shares of company stock valued at $9,689,847 over the last three months. Insiders own 5.40% of the company's stock.

Analysts Set New Price Targets

Several research firms have recently issued reports on PTGX. StockNews.com cut Protagonist Therapeutics from a "buy" rating to a "hold" rating in a research note on Tuesday. Truist Financial began coverage on Protagonist Therapeutics in a report on Monday, September 9th. They issued a "buy" rating and a $60.00 price objective for the company. BMO Capital Markets began coverage on Protagonist Therapeutics in a report on Friday, December 6th. They issued an "outperform" rating and a $62.00 price objective for the company. TD Cowen upgraded Protagonist Therapeutics to a "strong-buy" rating in a report on Wednesday, September 25th. Finally, The Goldman Sachs Group began coverage on Protagonist Therapeutics in a report on Friday, December 6th. They issued a "neutral" rating and a $47.00 price objective for the company. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Protagonist Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $53.78.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.